Friday 6 November 2026 Export SRRK’s income statement to Excel — free account

Scholar Rock Holding Corporation

SRRK Healthcare Biotechnology

Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.

EPS: +14.3%
Free cash flow: +8.88%
Total debt: +294.3%

Quarter to June 2026, against a year earlier

46.94 1.44 +3.16%

Follow SRRK

Alert me

Market cap: $5.5B
P/E: 0.0×
Fwd P/E: −7.3×
Dividend yield: —
F-score: 3/9
Altman Z: 1.14
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 12.00

Sold, $m 19.44

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	1	—
Sell	2	10	5	—	4	—	—	5	—	—	—	—

Insider Ownership 22.86%

Capital & Financial Ratios $m

Size

Market Cap 5,540.00

Revenue ttm 47.30

Net income ttm (408.59)

Free cash flow ttm (297.01)

Net debt Q (295.88)

Valuation

P/E 0.00

Forward P/E (7.27)

Price / sales 129.62

Forward P/S Powerpack

Price / FCF 0.00

Price / book 24.16

Financial health

Current ratio Q 7.02

Debt / equity Q 0.77

Interest coverage Q (24.10)

Growth

Revenue growth Q +605.03%

Operating income growth Q +2.86%

EPS, this year −1.37%

EPS, next year A +21.73%

Revenue, next year A −27.88%

EPS, past 5 yrs —

EPS, next 5 yrs A +27.07%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 94.43%

10-year low 10-year high

P/B against its own 10 years 93.90%

10-year low 10-year high

EV/Sales against its own 10 years 94.42%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	280	437	368	492
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	8	14	18	15
	288	451	385	507

	2023	2024	2025	Q'26
Payables	3	10	10	11
ST’ Debt	—	—	—	—
Other	0	—	—	—
	33	47	55	72

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	17.44%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(1.20%)	(1.93%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.84 Actual −0.84

−0.91 −0.89 −0.86 −0.83 −0.81

Q3 FY25 Miss −0.02

Q4 FY25 Miss −0.02

Q1 FY26 Miss −0.01

Q2 FY26 Met 0.00

Q3 FY26 — Nov 10

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−0.88	−0.90	Miss by 0.02
Q4 FY25	−0.86	−0.88	Miss by 0.02
Q1 FY26	−0.82	−0.83	Miss by 0.01
Q2 FY26	−0.84	−0.84	Met by 0.00
Q3 FY26	−0.87	—	Reports 10 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.83)	(0.84)	—	—	—
’25	(0.67)	(0.98)	(0.90)	(0.75)	(3.29)
’24	(0.59)	(0.60)	(0.66)	(0.60)	(2.47)
’23	(0.49)	(0.47)	(0.53)	(0.50)	(1.99)
’22	(0.21)	(1.06)	(0.55)	(0.46)	(2.26)
’21	(0.76)	(0.84)	(1.02)	(0.97)	(3.59)
’20	(0.58)	(0.65)	(0.79)	(0.79)	(2.81)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’22	33	—	—	—	33
’21	5	5	5	4	19
’20	5	4	3	3	15
’19	3	5	5	8	20

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(82)	(70)	—	—	—
’25	(79)	(77)	(69)	(75)	(300)
’24	(50)	(49)	(52)	(50)	(201)
’23	(43)	(33)	(32)	(37)	(145)
’22	(43)	(35)	(26)	(29)	(133)
’21	(27)	(32)	(36)	(32)	(127)
’20	3	(20)	(23)	(20)	(60)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(82)	(70)	—	—	—
’25	(79)	(77)	(69)	(76)	(301)
’24	(50)	(49)	(52)	(50)	(201)
’23	(43)	(33)	(32)	(37)	(145)
’22	(43)	(35)	(27)	(29)	(134)
’21	(29)	(33)	(37)	(33)	(132)
’20	2	(20)	(25)	(22)	(64)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	0	—	—	20	15	19	33	—	—	—	47		+110.7%	6	142	384	+722.9%
	Gross margin, %	100.00	0.00	0.00	100.00	100.00	100.00	100.00	—	—	—	0.00		0.0 pt	Powerpack Scholar Rock Holding Corporation’s next three years, line by line Analysts expect revenue to grow 722.9% a year to 2028 — faster than the 110.7% of the last 6 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(16)	(25)	(49)	(51)	(86)	(132)	(135)	(166)	(246)	(378)	(409)		+41.9%
	EBT margin, %	(4,276.25)	0.00	0.00	(248.88)	(561.47)	(700.46)	(405.21)	0.00	0.00	0.00	0.00		+4,276.3 pt
	Net income	(16)	(25)	(49)	(51)	(86)	(132)	(135)	(166)	(246)	(378)	(409)		+41.9%
Per share, $
Per share, $	Revenue	0.24	0.00	0.00	0.74	0.50	0.51	0.56	0.00	0.00	0.00	0.00		n/m
	Earnings	(10.11)	(15.30)	(3.15)	(1.85)	(2.81)	(3.59)	(2.26)	(1.99)	(2.47)	(3.29)	(3.32)		(11.7%)
	Cash flow	(9.45)	(13.30)	1.57	(2.29)	(1.96)	(3.45)	(2.23)	(1.74)	(2.01)	(2.62)	(2.27)		(13.3%)
	Capex	(0.50)	(0.22)	(0.10)	(0.11)	(0.13)	(0.14)	(0.02)	0.00	0.00	(0.01)	0.00		(39.7%)
	Free cash flow	(9.94)	(13.52)	1.47	(2.40)	(2.09)	(3.60)	(2.24)	(1.74)	(2.01)	(2.62)	(2.27)		(13.8%)
	Book value	17.49	34.09	6.81	4.10	8.48	4.69	4.37	2.70	3.69	2.14	1.94		(20.8%)
	Shares, m	2	2	16	28	31	37	60	83	100	115	122		+60.7%
Valuation, ×
Valuation, ×	P/E	0.00	—	—	0.00	0.00	0.00	0.00	—	—	—	0.00		0.0
	P/S	0.00	—	—	17.71	96.83	48.47	12.07	—	—	—	129.62		35.0
	P/B	0.00	—	—	3.21	5.72	5.30	2.19	—	—	—	24.16		3.3
	EV/Sales	0.00	—	—	10.23	76.29	37.59	6.46	—	—	—	123.36		26.1
	EV/FCF	(0.51)	—	—	(3.17)	(18.26)	(5.36)	(2.28)	—	—	—	(19.65)		(5.9)
Cash, $m
Cash, $m	Operating cash flow	(15)	(22)	25	(63)	(60)	(127)	(133)	(145)	(201)	(300)	(297)		+39.4%
	Capex	(1)	0	(1)	(3)	(4)	(5)	(1)	0	0	(1)	0		(3.0%)
	Free cash flow	(16)	(22)	23	(66)	(64)	(132)	(134)	(145)	(201)	(301)	(297)		+38.6%
Balance, $m
Balance, $m	Working capital	25	54	147	152	302	201	292	255	404	330	435		+32.9%
	Net debt	(27)	(58)	(176)	(153)	(316)	(205)	(266)	(231)	(387)	(268)	(296)		+29.0%
	Shareholders’ equity	28	56	107	113	261	172	260	225	369	245	254		+27.3%
Returns, %
Returns, %	ROA	(34.33)	(52.94)	(40.60)	(27.00)	(29.58)	(38.05)	(40.60)	(49.55)	(62.67)	(85.97)	(94.63)		(51.6) pt
	ROIC	(995.21)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		+995.2 pt
	ROE	38.80	59.83	(185.78)	(46.46)	(46.29)	(60.90)	(62.22)	(68.30)	(82.95)	(123.08)	(167.77)		(161.9) pt
People
People	Employees	—	50	65	93	119	145	114	150	196	289	—		+24.5%
	Revenue/emp, $m	0.00	0.00	0.00	0.22	0.13	0.13	0.29	0.00	0.00	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2022 · latest quarter Mar 2022 · fundamentals updated 25 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IMVT Immunovant, Inc.	$5.9B	— (loss-making)	—	—	n/m	−5.96% (below 0%: shrinking)	0.00%	0.00%	Compare
BLTE Belite Bio, Inc. Sponsored ADR	$5.8B	— (loss-making)	—	—	n/m	+64.67% (above 0%: growing)	—	0.00%	Compare
CGON CG Oncology, Inc.	$5.7B	— (loss-making)	— (loss-making)	+2,125.00% (above 0%: growing)	n/m	−67.60% (below 0%: shrinking)	(239.24%)	(7,467.68%)	Compare
KOD Kodiak Sciences Inc.	$5.7B	— (loss-making)	—	—	n/m	−33.86% (below 0%: shrinking)	0.00%	0.00%	Compare
SRRK Scholar Rock Holding Corporation	$5.5B	— (loss-making)	— (loss-making)	+605.03% (above 0%: growing)	n/m	+8.88% (above 0%: growing)	0.00%	0.00%
PTCT PTC Therapeutics, Inc.	$5.5B	— (loss-making)	42.2×	+69.57% (above 0%: growing)	n/m	+90.28% (above 0%: growing)	93.39%	7.02%	Compare
MANE Veradermics Incorporated	$5.4B	— (loss-making)	—	—	n/m	−8.81% (below 0%: shrinking)	—	0.00%	Compare
COGT Cogent Biosciences, Inc.	$5.1B	— (loss-making)	— (loss-making)	−69.41% (below 0%: shrinking)	n/m	−42.01% (below 0%: shrinking)	0.00%	0.00%	Compare
ERAS Erasca, Inc.	$4.6B	— (loss-making)	—	—	n/m	−4.67% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$5.6B	—	—	+69.57%	—	−7.38%	0.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 22 April 2026

Ownership

Directors and executive officers, together 10.30%

FMR LLC 11.90%

Invus Public Equities, L.P. 9.10%

Entities affiliated with Redmile Group, LLC 8.30%

Srinivas Akkaraju 5.90%

T. Rowe Price Associates, Inc. 5.80%

Samsara BioCapital, L.P. 5.30%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Scholar Rock Holding Corporation (SRRK) Latest News

20 Oct

Impact 4 · 8:00 AM · Business Wire

Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026

15 Oct

Impact 4 · 9:20 PM · Simply Wall St.

EMA Resubmission for Apitegromab Might Change The Case For Investing In Scholar Rock Holding (SRRK)

8 Oct

Impact 4 · 8:00 AM · Business Wire

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

25 Sep

Impact 4 · 12:35 PM · MT Newswires

Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says

17 Sep

Impact 4 · 12:06 AM

Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

15 Sep

Impact 4 · 7:16 PM

Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions

Impact 4 · 2:52 PM

Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says

14 Sep

Impact 5 · 10:30 PM

Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy

Impact 5 · 8:08 AM · InvestorsHub

Scholar Rock Shares Rise 9.1% After FDA Approves ISEMBYLD for Spinal Muscular Atrophy

Impact 5 · 5:00 AM · biopharmadive.com

Scholar Rock SMA drug approved by FDA

Impact 4 · 4:30 PM · Stocktwits

SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets

Impact 4 · 12:17 PM

Scholar Rock's Early FDA Approval on Spinal Muscular Atrophy Drug Seen as 'Positive Surprise,' UBS Says

11 Sep

Impact 5 · 7:31 PM · Stocktwits

Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours

Impact 5 · 6:25 PM

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

2 Sep

Impact 4 · 8:00 AM

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

22 Aug

Impact 4 · 7:09 AM

Is Scholar Rock Holding (SRRK) Fairly Valued On Its Apitegromab Regulatory Progress?

Impact 3 · 4:09 AM

Scholar Rock (SRRK) Streamlines Apitegromab Filings After Catalent Shift Is Regulatory Strategy De-Risking The Story?

21 Aug

Impact 4 · 9:06 AM

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

Impact 3 · 5:50 PM · Stocktwits

SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing

17 Aug

Impact 4 · 7:03 PM · MarketBeat

Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab

14 Aug

Impact 3 · 9:46 PM

Is Scholar Rock Holding Corporation (SRRK) Better Positioned than Novo Nordisk A/S (NVO) After Recent Setbacks?

13 Aug

Impact 3 · 9:29 AM · The Motley Fool transcript

Scholar Rock (SRRK) Q2 2026 Earnings Call Transcript

10 Aug

Impact 3 · 5:19 AM

Update: Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date

7 Aug

Impact 4 · 4:20 PM

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Impact 4 · 9:04 AM · MarketBeat

Scholar Rock Q2 Earnings Call Highlights

6 Aug

Impact 4 · 3:02 PM transcript

Scholar Rock Holding Corp (SRRK) (Q2 2026) Earnings Call Highlights: Dual Paths to FDA Approval ...

Impact 3 · 7:00 AM

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

20 Jul

Impact 4 · 8:00 AM

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

14 May

Impact 3 · 2:57 PM · The Motley Fool

This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO

Impact 3 · 2:51 PM · The Motley Fool

Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700%

Scholar Rock Holding Corporation

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Scholar Rock Holding Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 22 April 2026

Ownership

Scholar Rock Holding Corporation (SRRK) Latest News

20 Oct

15 Oct

8 Oct

25 Sep

17 Sep

15 Sep

14 Sep

11 Sep

2 Sep

22 Aug

21 Aug

17 Aug

14 Aug

13 Aug

10 Aug

7 Aug

6 Aug

20 Jul

14 May

SRRK metrics, ten years each

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Scholar Rock Holding Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 22 April 2026

Ownership

Scholar Rock Holding Corporation (SRRK) Latest News

20 Oct

15 Oct

8 Oct

25 Sep

17 Sep

15 Sep

14 Sep

11 Sep

2 Sep

22 Aug

21 Aug

17 Aug

14 Aug

13 Aug

10 Aug

7 Aug

6 Aug

20 Jul

14 May

SRRK metrics, ten years each

Stockrow Weekly